Toronto, Canada (PRWEB) March 05, 2013
The expiration of patents and other intellectual property rights for originator biologics over the next decade opens up opportunities for biosimilars to enter the market and increase competition. Despite the challenges associated with biosimilar drug development, many drug manufacturers are entering the race to develop biosimilars — especially for blockbuster mAbs. With increased clinical trial activity through Phase III, the ability to recruit patients into these important studies becomes a key stepping stone to Biosimilar commercial success.
Join our speaker, Rodeina Challand, Executive Director of Biosimilars Development at PRA , for an in-depth look at the challenges and solutions in conducting biosimilar trials.
A Q&A with the audience will follow the main presentation.
For more information about this event or to register, visit: http://xtks.in/xto565-event
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com/ContactUs.ashx
Karen Lim (416) 977-6555 ext 227
Read the full story at http://www.prweb.com/releases/2013/3/prweb10489362.htm.
Copyright©2012 Vocus, Inc.
All rights reserved